FRESCO-2: Fruquintinib
Arvind Dasari, MD, joins Rohit Gosain, MD, and Rahul Gosain, MD, of Oncology Brothers, to discuss the FRESCO-2 data and its impact on the colorectal cancer landscape.
Arvind Dasari, MD, joins Rohit Gosain, MD, and Rahul Gosain, MD, of Oncology Brothers, to discuss the FRESCO-2 data and its impact on the colorectal cancer landscape.
A real-world study found adding a PD-L1 inhibitor to cabozantinib offered no significant survival advantage for patients with metastatic kidney cancer who had already received…
In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic…
The Oncology Brothers are joined by Nina Sanford, MD; Jeffrey M. Ryckman, MD; and Harris Chengazi, MD, to discuss the treatment of patients with hepatocellular…
Compared with ruxolitinib, momelotinib improved mild, moderate, and severe anemia in patients with myelofibrosis who were naive to JAK inhibitors, according to the phase 3…
Maher Bitar, a senior White House intel officia, is a former pro-Palestinian activist who was a leader in Students for Justice in Palestine.
Fecal microbial transplantation followed by the right diet is as an effective treatment of ulcerative colitis.
A new survey showed that too many young people believe myths and misinformation related to skin cancer prevention.
Momelotinib achieved higher rates of transfusion independence compared with ruxolitinib.
Christina Matousek, MSN, RN, OCN, of the Smilow Cancer Hospital at Yale New Haven Health, speaks about what Oncology Nursing Month, observed every May, means…
Drs. Thomas Zilli and Pierre Blanchard join The Uromigos at APCCC 2024 to debate the use of radiation therapy in prostate cancer and oligometastatic disease.